

Schwerpunkt: Kolonkarzinom

Metastasiertes Kolorektales Karzinom: Fortschritte bei der Personalisierung der palliativen Systemtherapie (S. 36–43)

C. Köpping-Segerling, W. Schmiegel, M. Pohl

1. Robert Koch Institut (2015) Krebs in Deutschland 2011/2012, 10..Aufl. RobertKoch Institut, Berlin
2. Heinemann V, Weikersthal LF von, Decker T et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, openlabel, phase 3 trial. *Lancet Oncol* 2014; 15: 1065–1075
3. Schmiegel W, Buchberger B, Follmann M et al. S3-Leitlinie Kolorektales Karzinom. *Z Gastroenterol* 2017; 55(12): 1344–1498
4. Douillard JY, Oliner KS, Siena S et al. Panitumumab- FOLFOX4 treatment and RAS mutations in colorectal cancer. *N Engl J Med* 2013; 369: 1023–1034
5. Van Cutsem E, Lenz HJ, Kohne CH et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. *J Clin Oncol* 2015; 33(7): 692–700
6. Khattak MA, Martin H, Davidson A et al. Role of first-line anti.epidermal factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a metaanalysis of randomized clinical trials. *Clin Colorectal Cancer* 2015; 14 (2): 81–90
7. Loupakis F, Cremolini C, Salvatore L et al. FOLFOXIRI plus bevacizumab as first line treatment in BRAF mutant metastatic colorectal cancer. *Eur J Cancer* 2014; 50: 57–63
8. Fakih M, O'Neil B, Price TJ et al. Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors. *J Clin Oncol* 2019, 37 (suppl; abstr 3003)
9. Cremolini C, Loupakis F, Antoniotti C et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. *Lancet Oncol* 2015; 16: 1306–1315
10. Geissler M, Riera-Knorrenschild J, Tannapfel A et al. mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wildtype metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO- CRC0109). 2018 ASCO Meeting; Abstract 3509
11. Kopetz S, Grothey A, Yaeger R et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. *N Engl J Med* 2019 Sep 30. doi: 10.1056/NEJMoa1908075. [Epub ahead of print] PubMed PMID: 31566309
12. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. *N Engl J Med* 2018 Feb; 378(8): 731–9
13. Schwarzenbach H, Dave S. B. Hoon & Klaus Pantel. Cell-free nucleic acids as biomarkers in cancer patients *Nature Reviews Cancer* 2011; 11, 426–437

14. Løes IM, Immervoll H, Sorbye H et al. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. *Int J Cancer* 2016; 139(3): 647–656
15. Morelli MP, Overmann MJ, Dasari A et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. *Annals of Oncology* 2015; 26: 731–736
16. Siravegna G, Mussolin B, Buscarino M et al. Clonal evolution and resistance to EGFR blockade in the blood of colo-rectal cancer patients. *Nature Medicine* 2015; 21, 795–801
17. Venook AP, Niedzwiecki D, Innocenti F et al. Impact of primary (1^o) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). *J Clin Oncol* 2016; 34, (suppl; abstr 3504)
18. Lee MS, Advani SM, Morris J, et al. Association of primary (1^o) site and molecular features with progression-free survival (PFS) and overall survival (OS) of metastatic colorectal cancer (mCRC) after anti-epidermal growth factor receptor (αEGFR) therapy. *J Clin Oncol* 2016; 34, (suppl; abstr 3506)
19. Cremolini C, Antoniotti C, Lonardi S et al. Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC. *J Clin Oncol* 2019; 37(suppl): abstr 3508
20. Bennouna J, Sastre J, Arnold D et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. *Lancet Oncol* 2013; 14: 29–37
21. Tabernero J, Van Cutsem E, Lakomy R et al. Afibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. *Eur J Cancer* 2014; 50: 320–331
22. Tabernero J, Yoshino T, Cohn AL et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. *Lancet Oncol* 2015; 16: 499–508
23. Mayer RJ, Van Cutsem E, Falcone A et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. *N Engl J Med* 2015; 372: 1909–1919
24. Sartore-Bianchi A, Trusolino L, Martino C et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. *Lancet Oncol* 2016; 17(6): 738–746
25. Sartore-Bianchi A, Martino C, Lonardi S, et al. Phase II Study of Pertuzumab and Trastuzumab-emtansine (T-DM1) in Patients with HER2-positive Metastatic Colorectal Cancer: the HERACLES-B (HER2 Amplification for Colo-rectal cancer Enhanced Stratification, cohort B) Trial. *Annals of Oncology* (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246
26. Nakamura Y, Okamoto W, Kato T, et al. TRIUMPH: Primary Efficacy of a Phase II Trial of Trastuzumab (T) and Pertuzumab (P) in Patients (pts) with Metastatic Colorectal Cancer (mCRC) with HER2 (ERBB2) Amplification (amp) in Tumor Tissue or Circulating Tumor DNA (ctDNA): A GOZILA Sub-study. Nakamura Y, Okamoto W, Kato T et al. TRIUMPH *Annals of Oncology* (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246
27. Strickler JH, Zemla T, Ou F-S, et al. Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial. *Annals of Oncology* (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246

28. Guinney J, Dienstmann R, Wang X et al. The consensus molecular subtypes of colorectal cancer. *Nat Med* 2015; 21: 1350–56
 29. Le DT, Uram JN, Wang H, et al. Programmed death-1 blockade in mismatch repair deficient colorectal cancer. *J Clin Oncol* 2016; 34, (suppl; abstr 103)
 30. Overman MJ, Lonardi S, Wong KYM et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. *J Clin Oncol* 2018; 36(8): 773–779
-

Update: Das Hepatozelluläre Karzinom (S. 51–58)

C. Leyh, H. Wedemeyer

1. Galle PR, Forner A, Llovet JM et al. ASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J Hepatol* 2018; 69: 182–236
2. Keng VW, Largaespada DA and Villanueva A. Why men are at higher risk for hepatocellular carcinoma? *J Hepatol* 2012; 57: 453–454
3. Forner A, Reig M and Bruix J. Hepatocellular carcinoma. *The Lancet* 2018; 391: 1301–1314
4. Shimizu M, Tanaka T and Moriwaki H. Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis. *Semin Immunopathol* 2013; 35: 191–202
5. Cho YK, Kim JK, Kim WT, Chung JW. Hepatic Resection vs. radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. *J Hepatol* 2010; 51: 1284–1290
6. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in Advanced Hepatocellular Carcinoma. *N Engl J Med* 2008; 359: 378–390
7. Bruix J, Qin S, Merle P et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2017; 389: 56–66
8. Kudo M, Finn RS, Qin S et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *Lancet* 2018; 391: 1163–73
9. Abou-Alfa GK, Meyer T, Cheng AL et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. *N Engl J Med* 2018; 379: 54–63
10. Zhu AX, Park JO, Ryoo BY. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. *Lancet Oncol* 2015; 16: 859–70
11. Zhu AX, Kang YK, Yen CJ et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α -fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2019; 20: 282–296
12. Hiraoka A, Kumada T, Atsukawa M et al. Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma. *Oncol* 2019; 29: 1–7
13. Marrero JA, Kudo M, Venook AP et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. *J. Hepatol* 2016; 65: 1140–1147
14. Reig M, Torres F, Rodriguez-Lope C et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. *J. Hepatol* 2014; 61: 318–324

15. Xiang Q, Chen W, Ren M et al. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. *Clin Cancer Res* 2014; 20: 2959–70
 16. Rimassa L, Danesi R, Pressiani T, Merle P. Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma. *Cancer Treat Rev* 2019; 70: 20–28
 17. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017
 18. Kim HY, Park JW, Joo J et al. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma. *J Gastroenterol Hepatol* 2013; 28: 1756–61
 19. Burbach GJ, Zuberbier T. Hand-Fuß-Syndrom bei Tyrosinkinaseinhibitorentherapie. Empfehlung für die Praxis. *Urologe* 2013; 52: 1574–1578
 20. Cornberg M, Wong VW, Locarnini S et al. The role of quantitative hepatitis B surface antigen revisited. *J Hepatol* 2017; 66: 398–411
 21. Deterding K, Wedemeyer H. Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta. *AIDS Rev* 2019; 21: 126–134
 22. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. *Best Pract Res Clin Gastroenterol* 2012; 26: 401–12
 23. Ji F, Yeo YH, Wei MT et al. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. *J Hepatol* 2019; 71: 473–485
 24. Mettke F, Schlevogt B, Deterding K et al. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. *Aliment Pharmacol Ther* 2018; 47: 516–525
 25. Greten TF, Malek NP, Schmidt S et al. Diagnostik und Therapie des hepatozellulären Karzinoms. Leitlinienprogramm Onkologie. S3-Leitlinie hepatozelluläres Karzinom. 2013
 26. Vitale A, Peck-Radosavljevic M, Giannini EG et al. Personalized treatment of patients with very early hepatocellular carcinoma. *J Hepatol* 2017; 66: 412–423
 27. Kirstein MM, Schweitzer N, Ay N et al. Experience from a real-life cohort: outcome of 606 patients with hepatocellular carcinoma following transarterial chemoembolization. *Scand J Gastroenterol* 2017; 52: 116–124
 28. Nault JC, Galle PR, Marquardt JU. The role of molecular enrichment on future therapies in hepatocellular carcinoma. *J Hepatol* 2018; 69: 237–247
 29. Owusu Sekyere S, Schlevogt B, Mettke F et al. HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection. *Liver Cancer* 2019; 8: 41–65
 30. Zhu AX, Finn RS, Edeline J et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. *Lancet Oncol* 2018; 19: 940–952
 31. El-Khoueiry AB, Sangro B, Yau T et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. *Lancet* 2017; 389: 2492–2502
 32. Scheiner B, Kirstein MM, Hucke F et al. Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. *Aliment Pharmacol Ther* 2019; 49: 1323–1333
-

PHARMAFORUM:

PARP-Inhibition beim fortgeschrittenen Ovarialkarzinom: Rucaparib in Erhaltungs- und Rezidivtherapie (S. 65)

1. Coleman RL et al. Lancet 2017; 390: 1949–1961
2. Leitlinienprogramm Onkologie. Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren 3.0 (Januar 2019), AWMF-Registernr. 032/035OL
3. Clovis Oncology Inc. Fachinformation Rubraca[®], Stand Februar 2019